ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

List of diseases spread by deer tick grows, including malaria-like problems and potentially fatal en...

Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients

Lyme disease confirmed in humans from southern states

The Worst Foods to Eat When You're Sick, and the Best Ones

The Lyme disease spirochete Borrelia burgdorferi induces inflammation and apoptosis in cells from do...

Scientists Reveal Quirky Feature of Lyme Disease Bacteria

Lyme Disease Activists Take Fight to Washington D.C.

Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial

Can light therapy help the brain?

In a warmer world, ticks that spread disease are arriving earlier, expanding their ranges

 
Print Page
Email Article

Clinical Results Suggest Drug Could Rival COX-2 Inhibitors in Treating Osteoarthritis

  [ 92 votes ]   [ Discuss This Article ]
www.ProHealth.com • June 21, 2002




The results of the first phase III clinical trials for the new osteoarthritis drug licofelone, have shown comparable efficacy to conventional NSAIDs but with excellent gastrointestinal (GI) and general tolerability. These results are similar to those achieved in the original development of COX-2 inhibitors; however, the action of licofelone should also avoid the possible disadvantages of COX-2 inhibitors and may therefore offer additional benefits for the treatment of osteoarthritis (OA).

According to data presented at the 2002 European League Against Rheumatism (EULAR) congress in Stockholm, licofelone inhibits both 5-LOX and COX enzymes in the inflammatory pathway and appears in theory, and now in clinical trials, to offer benefits over selective COX-2 inhibitors in the treatment of osteoarthritis. The most recent data presented by Professor Jean-Yves Reginster, of the University of Liege, Belgium, show licofelone to be as effective as the traditional NSAID, naproxen and with excellent GI and general tolerability.

"The trials in which we were involved start to show that our expectations for the benefits of 5-LOX/ COX inhibitors in treating osteoarthritis are well founded. Licofelone appears to offer comparable efficacy to the highly effective treatment naproxen, but with excellent GI, renal, hepatic and general tolerability," Reginster said.

Current treatment options for the inflammation and pain of osteoarthritis include conventional NSAIDs (such as the naproxen used in this study) and selective COX-2 inhibitors. Conventional NSAIDs effectively inhibit the COX-1 and COX-2 pathway, but have a high risk of adverse GI events. Selective COX-2 inhibitors have remained the main focus of research due to their early success and major pharmaceutical backing. Currently available COX-2 inhibitors have also demonstrated a reduction in gastrointestinal effects compared with the traditional NSAIDs.

However, it is now becoming clear that some COX-2 inhibitors may also be associated with an increased risk of GI events, and it is now being suggested, through the development of licofelone, that the balanced inhibition of the 5-LOX and COX pathways may provide a new alternative with an optimal benefit/risk ratio.

Professor Stefan Laufer, University of Tuebingen, Germany who is the researcher credited with discovering licofelone commented, “An extensive, published, pre-clinical program has demonstrated the anti-inflammatory and analgesic efficacy of licofelone. These results are now being confirmed in phase III studies, the first of which have been presented today. Licofelone has passed the stage of being interesting research and has now become a real potential alternative in optimizing the future treatment of osteoarthritis. We look forward to seeing the next available data which we hope will further support these findings and allow the companies involved to make a license submission to support the availability of the treatment for clinicians use as soon as possible."




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Free Download: Fibro Friendly Snack Recipes

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Three-Step Strategy to Reverse Mitochondrial Aging Three-Step Strategy to Reverse Mitochondrial Aging
Natural Support for Mood, Sleep and Mental Focus? L-theanine Natural Support for Mood, Sleep and Mental Focus? L-theanine
Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed
Natural Relief for Soreness, Pain and Swelling – Putting Out the Fire
Help for Soreness and Swelling: What Do Silkworms Have to Do With It? Help for Soreness and Swelling: What Do Silkworms Have to Do With It?

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing